Article Text

other Versions

PDF
YY1 expression predicts favourable outcome in follicular lymphoma
  1. Khimara Naidoo1,
  2. Vanessa Clay2,
  3. Judith A Hoyland3,
  4. Ric Swindell4,
  5. Kim Linton1,4,
  6. Timothy Illidge1,4,
  7. John A Radford1,4,
  8. Richard J Byers1,2
  1. 1School of Cancer and Enabling Sciences, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK
  2. 2Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
  3. 3School of Biomedicine, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK
  4. 4The Christie NHS Foundation Trust, Manchester, UK
  1. Correspondence to Dr R J Byers, Department of Histopathology, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK; richard.byers{at}cmft.nhs.uk

Abstract

Aims Follicular lymphoma is the second most common type of non-Hodgkin's lymphoma worldwide. The majority of patients diagnosed as having follicular lymphoma have an indolent form of the disease, but a subset of patients have aggressive disease with a shorter survival interval. Optimal treatment stratification requires a distinction between these two groups, though there are presently few prognostic biomarkers available. The transcription factor YY1 has been shown to play an important role in cancer biology. The authors have previously reported a correlation of Yin Yang 1 (YY1) mRNA levels with survival in FL. This study aimed to validate these findings at the protein level.

Methods Quantification of YY1 protein was carried out on 26 FL biopsy samples using quantum dot labelled immunohistochemistry. Ki-67 percentage, grade, YY1 protein levels and T cell and macrophage markers were used in a multivariable analysis for survival in 26 cases of FL.

Results Expression levels of YY1 protein were significantly increased in patients alive in comparison with those dead after follow-up (p≤0.025). Kaplan–Meier analysis showed association of higher expression levels of YY1 with longer survival (p≤0.01) (hazard ratio 3.33, 95% CI 1.26 to 8.85). The multivariable analysis identified YY1 protein level as the strongest predictor of outcome (p≤0.018), with none of the other markers being significantly associated with outcome.

Conclusion These results support the prognostic utility of YY1 in FL, indicating potential as a clinical biomarker.

  • Follicular lymphoma
  • Yin Yang 1
  • BCL-2
  • quantum dots
  • lymphoma

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by a BSc studentship from the Pathological Society of Great Britain and Ireland.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.